schmitt test results scanned

05/26/2015 3:08:46 PMTO:

LabCorpLaboratory Corporation o lT n ir le i|

FROM: LA BCORP LCLS BULK TO: 4 4 3 7 1 6 0 4 1 9Damanhuri Alkaitis, M.D.

LabCorp Raritan 69 First Avenue

LABCORP

' / V of 6

Specimen Number134-348-0382-0 Patient ID Cootrol Number Account Number

19769532 Accnunt Phone Number443-716-0420 RouteBR

Patient List Namec r n M T ’T'P Account AdcIfTSl

Pad cot First NameROBERTPatient SS#

Age (Y/M/D)22/11/23

Patient Middle Nime

Patient Phone443-875-4733

Date qJ Birth05/21/92 Sea

M

Total Volume

Fasting

122 DEFENSE HWY #222 ANNAPOLIS MD 21401

4254 KINGS RD EDGEWATER MD

Patient Address

21037Additional Information

UPIN: A60751Date aod Time Collected 05/14/15 00;00 Date Eoteted Date aod Time Reported Physician Name NPI Physician ID

0 5 / 1 4 / 1 5 0 5 / 2 6 / 1 5 1 5 : 0BET A L K A I T I S , D 1 5 6 8 4 5 1 3 7 5

Tests OtderedIFE and PE, Serum; Panel 083824; Anticardiolip Ab, XgA/G/M, Qn; GH1 Antibody IgG, XgM; Sjogren's Ab, Anti-SS-A/-ss-B; a n a w/Reflex; Methylmalonic Acid, Serum; Rheumatoid Arthritis Factor; Vitamin D, 25-Hydroxy; Cortisol; Anti-dsDNA Antibodies; t-Transglutaminase (tTG) IgA; t-Transglutaminase (tTG) IgG; VGCC Antibody; Creatinine, Serum; ALT (SGPT); RPR; Sedimentation Rate-Westergren; C-Reactive Protein, Quant; Thyroid Peroxidase (TPO) Ab; Creatine Kina3e,Total,Serum; Aldolase; Ambiguous Te3t Order_____________________________________________

LAB || T E ST S _____________________ RESULTIFE and PE, serumImmunoglobulin G, Qn, Serum 619Immunoglobulin A, Qn, Serum 166Immunoglobulin M, Qn, Serum 14Protein, Total, Serum 6.4Albumin 4.1Alpha-l-Globulin 0.2Alpha-2-Globulin 0.6Beta Globulin 1.0Gamma Globulin 0.5M-Spike Not observedGlobulin, Total 2.3A/G Ratio 1 •8Immunofixation Result, Serum

An apparent normal immunofixation Please note:Protein electrophoresis scan will

courier delivery.

T LAG UNITS REFERENCE INTERVAL

mg/dL 700 - 1600 01mg/dL 91 - 414 01mg/dL 40 - 230 01g/dL 6.0 - 8.5 01g/dL 3.2 - 5.6 01g/dL 0.1 - 0.4 01g/dL 0.4 - 1.2 01g/dL 0.6 - 1.3 01g/dL 0.5 - 1.6 01g/dL Not Observed 01g/dL 2.0 - 4.5

0.7 - 2.00101

via computer, mail, or

01<1.00 01

to the negative cutoff.Non Reactive 01

GPL U/mL 0 - 1 4 01Negative: <15Indeterminate : 15-20Low-Med Positive: >20 - 80High Positive s >80

1 3 4 - - 3 4 8 - 0 3 8 2 - 0 | Seq # 3494

LOW

LOW

Panel 083824HIV 1/0/2 Abs-ICMA HIV 1/0/2 Abs-index Value < 1.00

i H U K A v a i u w . ----------------------- - -

HIV 1/0/2 Abs, Qual Non Reactive

Anticardiolip Ab, igA/G/M, QnAnticardiolipin Ab,lgG,Qn <9

ROBERT1 SC H M IT T ,_________________________________

05/26/15 15:08 ET FINAL REPORTThis document contains private and confidential health infonnatlon protected by state and federal law.If you have received (his document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

0 2 0 0 4 -1 5 Laboratory Corporation of America ® Holding All Rights Reserve

DOCl Vet: 1.4

05/26/2015 3:08:46 PM FROM:LABCORPLCLSBULK TO: 4437160419 LABCORP ol 6TO: Damanhuri Alkaitis, M.D.

LabCorpLaboratory Corporation ol Xa w e j I


Raritan, NJ 08869-1800 Phone: 800-631-5250Patient NameSCHMITT, ROBERT

Spedmeo Number134-348-0382-0

Account Number

1 9 7 6 9 5 3 2Pad eat ID Coctrol Number Date tod Time Collected Date Reported Sex Age(Y/M/D) Dale of Birth

0 5 / 1 4 / 1 5 0 0 : 0 0 0 5 / 2 6 / 1 5 M 2 2 / 1 1 / 2 3 0 5 / 2 1 / 9 2

TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB

Anticardiolipin Ab,IgM,Qn

Anticardiolipin Ab,IgA,Qn

<9

<9

MPL U/rtiL 0 - 12Negative: <13Indeterminate: 13 - 20Low-Med Positive: >20 - 80High Positive: >8 0

APL U/mL 0 - 11Negative: <12Indeterminate: 12 - 20Low-Med Positive: >20 - 80High Positive: >80

01

01

C»il Antibody IgG, IgMAnti-GMl (IgM)* <1:100 titer 02

Reference Range:Negative: < 1:100 titer Positive: => 1:100 titerTiters of less than 1:400 may not be clinically significant.We suggest clinical correlation to ascertain the significance of the low titers.

Antibodies against glycolipids (GM1, GDla, GDlb, GQlb, asialo GM1, and sulfatides) are present in patients with Guillain-Barre syndrome (GBS), IgM paraproteinemic neuropathy, and chronic demyelinating polyneuropathy (CIDP). Antibodies to one or more glycolipids are present in 60-70% of patients with GBS. The titers of anti-glycolipid antibodies are higher in acute phase and decrease in association with clinical improvement. Antibodies against GM1 and/or GDlb are frequently present in acute phase GBS. The two antibodies together occur in about 20% of these cases, anti-GMl without anti-GDlb antibodies in about 10% and anti-GDlb without anti-GMl antibodies in about 10% of GBS patients. Antibodies against GQlb of igG isotype are present in 95% of patients with Miller Fisher syndrome (MFS). The titers of these antibodies fluctuates with disease activity. IgM paraproteinemia is often associated with peripheral neuropathies. These antibodies are present in one half of patients with specificity for SGPG, GDlb and other gangliosides. Anti-GMl IgM antibodies are usually associated with motor-dominant or sensorimotor neuropathies. These antibodies are also elevated in diseases other than multifocal neuropathies such as GBS, CIDP and other immunological diseases.

♦This test has been developed and performance parameters have been validated by IMMCO Diagnostics, Inc. This test has not been approved by the U.S. Food and Drug Administration

fSCHMITT, ROBERT |05/26/15 15:08 ET FINAL REPORTThis Uaruincnl contains private and confidential health information protected by state and federal law.If you have received this document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

1 13 4 - 3 4 8 - 0 3 8 2 - 0 | Seg tt W.

Page 2 of 5© 2 0 0 4 -1 5 Laboratory Corporation of America Hold

All Rights Resei DOC1 Ver:

05R6/2015 3:08:46 PM FROM: LABCORP LCLS BULK TO:4437160419 LABCORP1 Damanhurl Alkaitis, M.D.

of 6

LabCorpUhotMotyLabCorp Raritan 69 First Avenue

Raritan, NJ 08869-1800 Phnne:

SCHMITT, tROBERT Patient Name Specimen Number134-348-0382-0Aecotiot Number

1 9 7 6 9 5 3 2Patient ID

T E S T S

Cootrol Number

RESULT

Date and Time Collected 0 5 / 1 4 / 1 5 0 0 :0 0

FLAG

Date Reported 0 5 / 2 6 / 1 5

UNITS

Sex Age(Y/M/D)M 2 2 / 1 1 / 2 3

REFERENCE INTE1

Date of Birth 0 5 / 2 1 / 9 2

IV AL LAB(FDA); however, US FDA approval is not required for clinical use. it is not intended that clinical diagnosis and patient management decisions be made using these results alone.

This test has been validated using serum samples. The manufacturer has not determined the efficacy of this test when performed on CSF, plasma, joint or pleural fluid specimens. The performance characteristics of this test were

t determined by IMMCO Diagnostics Inc.Anti-GMl (IgG)* <1:100 titer 02

Reference Range:Negative: < 1:100 titer Positive: => 1:100 titer

Sjogren's Ab, Anti-SS-A/-SS-BSjogren's Anti-SS-A Sjogren's Anti-SS-B

ANA w/ReflexANA Direct

Methylmalonic Acid, SerumRheumatoid Arthritis FactorRA Latex Turbid.

Vitamin D, 25-HydroxyVitamin D deficiency has been defined by tne institute ot Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).1. IOM (Institute of Medicine). 2010. Dietary reference

intakes for calcium and D. Washington DC: The

<0.2 AI 0.0 - 0.9 01<0.2 AI 0.0 - 0.9 01

Negative Negative 01337 nmol/L 0 - 378 03

9.0 IU/mL 0.0 - 13.9 01

14.3 Low ng/mL 30.0 - 100.0 01■»

National Academies Press.2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine society clinical practice guideline. JCEM. 2011 Jul; 96(7)s1911—30.

Cortisol 4.6 ug/dLCortisol AM Cortisol PM

2.3 - 19.4 016.2 - 19.42.3 - 11.9

| SCHMITT, ROBERT I ___________05/26/15 15:08 ET FINAL REPORTThis document contains private and confidential health infonnadon protected by state and federal law.

I f you have received this document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

| 1 3 4 - 3 4 8 - 0 3 8 2 - 0 I S e q # 3 4 9 4 ~ (

Page 3 of 5© 2004-15 Laboratory Corporation of America ® Holdings

All Rights Reserved DOC l Ver: 1.49

05/26/2015 3:08:46 PM FROM: LABCORP LCLS BULK TO: 4437160419 LABCORP JO : Damanhuri Alkaitis, M.D.

LabCprpLabCorp Raritan 69 First Avenue

Raritan. NJ 0SS69-1800 Phone: 800-631-52*

SCHMITT, ROBERTPan an Name Sped men Number

1 3 4 - 3 4 8 - 0 3 8 2 -Account Number

1 9 7 6 9 5 3 2Patient ID Control Number Date and Time Collected

C 5 / 1 4 / 1 5 0 0 : 0 0Date Reported 0 5 / 2 6 / 1 5

SeaM

Age(Y/M/D)2 2 / 1 1 / 2 3

Datee0 5 / 2

TEST S RES tJLT h a g UNITS REFERENCE INTERVAL

Anti-dsDNA Antibodies Anti-DNA (DS) Ab Qn

t-Transglutaminase (tTG) IgA <2

IU/mL 0 - 9Negative <5Equivocal 5 - 9Positive >9

U/mL 0 - 3Negative 0 - 3Weak Positive 4 - 10Positive >10

Tissue Transglutaminase (tTG) has been identified as the endomysial antigen. Studies have demonstrated that endomysial IgA antibodies have over 99% specificity for gluten sensitive enteropathy.

t-Transglutaminase (tTG) IgG 2 U/mL 0 - 5Negative 0 - 5Weak Positive 6 - 9 Positive >9

VGCC Antibody Negative NegativeResults for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Creatinine, SerumCreatinine, Serum 0.75 Low rtig/dL 0.76 - 1.27eGFR if NonAfricn An 130 mL/min/l.73 >59eGFR If Africn Am 151 raL/min/1.73 >59

ALT (SGPT) 25 IU/L 0 - 4 4RPR Non Reactive Non ReactiveSedimentation Rate-Westergren

2 mra/hr 0 - 1 5C-Reactive Protein, Quant 0.8 mg/L 0.0 - 4.9

Thyroid Peroxidase (TPO) Ab 316 High IU/mL 0 - 3 4

I s c h m i t t, Ro b e r t" | 134-348-0382-0 Sci05/26/15 15i08 ET FINAL REPORT Page 4 ofTUi document contains private and confidential health information protected by atate and federal law. © 2004-15 Laboratory Corporation of America « If you have received das document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0 All Riph1

DOC

05/26/2015 3:08:46 PM FROM: LABCORP LCLS BULK TO : 4437160419 LABCORP fTO: Damanhuri Alkaitis, M.D.

La b C o rpLaboratory Corporation o f & m *rb a| ~~


Raritan, N J 0 8 8 6 9 - 1 8 0 0 Phone: 800-<

SCHMITT, ROBERTPabMI Name Specimen N

134-348-1Accouat Number

1 9 7 6 9 5 3 2Patieor ID Control Number Date and Time Collected

0 5 / 1 4 / 1 5 0 0 : 0 0

Date Reported 0 5 / 2 6 / 1 5

SexM

Age(Y/M/Dl2 2 / 1 1 / 2 3

T EST S RESULT FLAG U N ITS R EFER EN C E IN I2

Creatine Kinase,Total,Serum 98 U/L 2 4 - 2C

Aldolase 4 . 6 U/L 3 . 3 - 1C

Ambiguous Test OrderTest not performed. The test requested has been discontinued and o: is no longer available. Please refer to LabCorp*s online Directory of Services for current test offerings or contact your LabCorp representative for assistance.Test: MATA

01 RN LabCorp Raritan Dir: Araceli B Reyes, HD69 First Avenue, Raritan, NJ 08869-1800

02 GK Iiranco Diagnostic Inc Dir: Thomas Shanahan, PhD640 Ellicott Street, Buffalo, NY 14203-1245

03 BN LabCorp Burlington Dir: William F Hancock, HD1447 York Court, Burlington, NC 27215-3361

For Inquiries, the physician may contact Branchs 800-631-5250 Lab: 800-631-5250

1 SCHMITT, ROBERT05/26/15 15:08 ET

134 - 3 48 -0 3 82

FINAL REPORT Pa

Laboratory Corporation o f America Special Chemistry Department Raritan, New Jersey

Serum Imtnunofixation

05/26/2015 3:08:46 PM FROM: LABCORP LCLS BULK 70:4437160419 LABCORPTO: Damanhuri Alkaitls, M.D.

Accession No: Total Protein: Patient Name: Patient Id: Birthdate:

1343480382096.4SCHMITT,ROBERT

21-MAY-1992

Account No./Name: D ID :

Account Address 1: Account Address 2: Account Address 3:

19769532-Damanhuri Alkai ALKAITIS D

122 DEFENSE HWY <222 ANNAPOLIS, MD 21401

SPIFE SPE Split Beta Sample 56 05-15-2015 1 3 i 1 6 i 44«55

Fraction % g/dL g/dL RangeAlbumin 63.3 4.1 3.2 5.6Alpha 1 3.0 0.2 0.1 0.4Alpha 2 9.0 0.6 0.4 1.2Beta 16.3 1.0 0.6 1.3Gamma 8.4 0.5 0.5 1.6Total 6.4 6.0 8.5

Immunofixation Interpretation:An apparent normal immunofixation pattern

schmitt test results scanned

Documents